We further identify additional potential therapeutic targets for Y537S ERα-expressing breast cancers (KMT2C/2D complexes) and for the ESR1-YAP1 fusion (26S proteasome) for which no prior targets were known. Here, YAP1 is linked to breast carcinoma.